Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space

Sarah Orfanos; Ibrahim El Husseini; Thomas Nahass; Jared Radbel; Sabiha Hussain

doi:10.1183/23120541.00455-2020

Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space

ERJ Open Res. 2020 Oct 5;6(4):00455-2020. doi: 10.1183/23120541.00455-2020. eCollection 2020 Oct.

Authors

Sarah Orfanos^{1

2}, Ibrahim El Husseini^{1

2}, Thomas Nahass¹, Jared Radbel¹, Sabiha Hussain¹

Affiliations

¹ Dept of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
² Both authors contributed equally to this work.

Abstract

#COVID19-induced ARDS is partly explained by the presence of microthrombi, motivating the use of thrombolytics. This study shows that thrombolytics decrease dead space ventilation in COVID-19 ARDS patients. https://bit.ly/2GdM44a.